Merdury Biopharmaceutical

Merdury Biopharmaceutical EBITDA per Share

The EBITDA per Share of Merdury Biopharmaceutical (6932.TWO) as of Nov 4, 2026 is -0.15 TWD. In the previous year, EBITDA per Share was -0.12 TWD — a change of 26.84% (lower).

EBITDA per Share

-0.15TWD

YoY

26.84%

Last updated:

EBITDA per Share of Merdury Biopharmaceutical is 2025 -0.15 TWD. EBITDA per Share of Merdury Biopharmaceutical was 2024 -0.12 TWD. It decreases by 26.84% lower compared to the previous year.

The Merdury Biopharmaceutical EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-0.00 TWD
Jan 1, 2020
-0.00 TWD
Jan 1, 2021
-0.01 TWD
Jan 1, 2022
-0.08 TWD
Jan 1, 2023
-0.10 TWD
Jan 1, 2024
-0.12 TWD
Jan 1, 2025
-0.15 TWD
The Merdury Biopharmaceutical EBITDA per Share history
YEAREBITDA per ShareYoY
-0.15TWD+26.84%
-0.12TWD+14.00%
-0.10TWD+34.84%
-0.08TWD+563.59%
-0.01TWD+2,422.86%
-0.00TWD-6.25%
-0.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp develops and manufactures pharmaceutical products including Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, and multi-ingredient antihypertensive drugs. The company utilizes its StackDose platform to create controllable time-dissolving tablets for instant or sustained drug release. Products are primarily sold in Taiwan and the United States, targeting markets for drugs that do not meet special medical needs, difficult generics, and second-class new drugs. The company's revenue comes from the sale of these pharmaceutical products to customers in both regions. The firm's StackDose technology enables the development of specialized drug formulations that control the timing of drug effectiveness, differentiating its product range. This focus on innovative delivery systems supports sales in the pharmaceutical markets of Taiwan and the U.S., where demand exists for advanced generic and specialty medications. The company's product portfolio aligns with its strategic focus on non-special medical need drugs and second-class new drugs. Merdury Biopharmaceutical Corp targets healthcare providers and pharmacies in Taiwan and the United States as its primary customers. The company's self-developed StackDose platform allows for the creation of unique drug delivery systems that are sold under the company's own product lines. Sales of Sildenafil, Metformin, Tadalafil, and other key products form the core of the company's revenue streams. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

EBITDA per Share of Merdury Biopharmaceutical is -0.15 TWD in 2025.

EBITDA per Share of Merdury Biopharmaceutical changed from -0.12 TWD to -0.15 TWD, representing a 26.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical